A network of colleagues, they form our client base

"@Dev ..you guys from Crypto Valley Zug or just a post box here ? Asking this for the 3rd time now"

YES WE ARE ZUG BASED in the heart of Switzerland.

Core team members based in Zug from 10 to 15 years. 

This the EU hub for Biotech and Pharma, hence the main reason why we are here.  Please review the white papers for our full details.

also review the video - it highlights the core 20 biotechs that are based here.
J&J, Biogen, Amgen, Roche, Novartis, Takeda, Shire, Baxter, these are just a few...many more.

Thanks BioNT

"Is there a minimum amount you need to gather in investments in order for the project to start?"

We did not set a minimum, as our private investors will also come through in the October, they - we are awaiting FINMA approval based on a KPMG audit.
This will be the 1st ICO with a Swiss Prospectus, expected early next week.

The project has 3 phases, dependent upon how which raise will drive the speed of development, 1st the pricing system (push the beta into commercial), 2nd the drug forecasting platform (beta to production, and then commercial) and finally the 3rd decentralised trading platform - this will be a significant phase of the project to provide trading signals for traders and investors around the world. 

" I will follow your campaign. but I want to ask. How will you convince pharmaceutical companies to use this technology? I understand the part about the pricing of medicines. and there are many domestic companies besides international companies. Which country is your first destination? I think I'm a little confused."

We already have beta a version of the pricing system, we don't need to convince pharma companies to use the system, they need the system due to the changing complexity of government price reporting, US and EU which is mandatory.  The target base for user's is Swiss based Biotech (in Zug-Zurich) & US based (Boston-Bay). Hope this helps?  

And you are right - the reference source is 2022 for $1.2Tr global revenue. Thank you.

The market cap of the top 100 pharma companies is already $2.2Tr as stated.

Btw, we do not work for large pharma, lets make this clear...

We only work for small starts up Biotech's, Orphan Diseases, and Oncology (chimeric immunoreceptors, T cell receptors, artificial T cell receptors or CAR-T)

This is a specialist area, but incredibly risky and volatile, we try and avoid big pharma.

These small Biotechs  ($100m - $5Bn, this is small in pharma world), they will benefit from our specialist solutions - it will allow them to secure funding to develop life saving molecules - they are not thinking about Porches or Yachts, ONLY PATIENTS!   

This is detailed in the white paper, thank you for questions and support.

Btw, we are based in Zug Switzerland, the team members have been here between 10-15 years. This has been my family home for the past 15 years.

The revenue buyback is locked for 25 years.

The rational is to drive token value ( remember profit can be adjusted, not revenue )

The project is going through FINMA approval (this is the Swiss financial regulator) this will be the 1st ICO to file a prospectus - hence the some what slow start.  We also have road shows planned in London, Geneva, Zurich, Singapore and HongKong. We will post the dates, times and venues.

We will have live demos of the beta version of the applications, and Q&A - we are very excited and welcome your support.